Stivarga Approved for Metastatic Colorectal Cancer

Share this content:

Onyx and Bayer HealthCare announced that the FDA has approved Stivarga (regorafenib tablets) for the treatment of patients with metastatic colorectal cancer who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy).

This approval is based on study results from the Phase 3 CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) that demonstrated improvement in overall survival [HR=0.77 (95% CI, 0.64–0.94), two-sided p=0.0102] and progression-free survival [HR=0.49 (95% CI, 0.42–0.58), two-sided p<0.0001] compared to placebo in patients with metastatic colorectal cancer whose disease had progressed after approved standard therapies.  Median overall survival was 6.4 months with Stivarga vs. 5.0 months with placebo; median PFS was 2.0 months with Stivarga vs. 1.7 months with placebo.

Stivarga is an oral multi-kinase inhibitor that inhibits various kinases within the mechanisms involved in tumor growth and progression–angiogenesis, oncogenesis and the tumor microenvironment.

Stivarga will be available in 40mg strength film-coated tablets in 28-count bottles.

For more information call (866) 639-2827 or visit

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs